Selective Inhibition of PDE4B Reduces Methamphetamine Reinforcement in Two C57BL/6 Substrains
Abstract
:1. Introduction
2. Results
2.1. Sex and Substrain Differences in Oral MA Reinforcement
2.1.1. Acquisition
2.1.2. Dose–Response Testing
2.1.3. Demand Testing
2.2. A33 Effects on MA Reinforcement and Cue-Elicited Drug Seeking
2.2.1. Maintenance of Established MA Self-Administration
2.2.2. Cue-Elicited MA Seeking
2.3. A33 Effects on Sucrose Reinforcement
3. Discussion
3.1. Selective PDE4B Inhibition by A33 Reduces MA Reinforcement
3.2. Selective PDE4B Inhibition by A33 Does Not Alter Cue-Elicited MA Seeking
3.3. Substrain Differences in Oral MA Reinforcement
3.4. Sex Differences in Oral MA Reinforcement
4. Materials and Methods
4.1. Subjects
4.2. Drugs
4.3. Operant Conditioning for Oral MA Reinforcement
4.4. A33 Dose Response
4.5. MA Dose- and Demand-Response Testing
4.6. Cue-Elicited MA Seeking
4.7. Data Analyses
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Twillman, R.K.; Dawson, E.; LaRue, L.; Guevara, M.G.; Whitley, P.; Huskey, A. Evaluation of trends of near-real-time urine drug test results for methamphetamine, cocaine, heroin, and fentanyl. JAMA Netw. Open 2020, 3, e1918514. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54); Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration: Rockville, MD, USA, 2019. Available online: https://www.samhsa.gov/data/sites/default/files/cbhsq (accessed on 3 February 2021).
- Hedegaard, H.; Miniño, A.M.; Warner, M. Drug Overdose Deaths in the United States, 1999–2018 (NCHS Data Brief No. 356); National Center for Health Statistics: Hyattsville, ML, USA, 2020. Available online: https://www.cdc.gov/nchs/data/databriefs/db356-h.pdf (accessed on 2 February 2021).
- London, E.D.; Simon, S.L.; Berman, S.M.; Mandelkern, M.A.; Lichtman, A.M.; Bramen, J.; Shinn, A.K.; Miotto, K.; Learn, J.; Dong, Y.; et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch. Gen. Psychiatry 2004, 61, 73–84. [Google Scholar] [CrossRef]
- Volkow, N.D.; Chang, L.; Wang, G.J.; Fowler, J.S.; Franceschi, D.; Sedler, M.J.; Gatley, S.J.; Hitzemann, R.; Ding, Y.S.; Wong, C.; et al. Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am. J. Psychiatry 2001, 158, 383–389. [Google Scholar] [CrossRef]
- Fiorentini, A.; Cantù, F.; Crisanti, C.; Cereda, G.; Oldani, L.; Brambilla, P. Substance-Induced Psychoses: An Updated Literature Review. Front. Psychiatry 2021, 12, 694863. [Google Scholar] [CrossRef]
- Iyo, M.; Bi, Y.; Hashimoto, K.; Inada, T.; Fukui, S. Prevention of methamphetamine-induced behavioral sensitization in rats by a cyclic AMP phosphodiesterase inhibitor, rolipram. Eur. J. Pharmacol. 1996, 312, 163–170. [Google Scholar] [CrossRef]
- Chen, Y.; Yang, C.; Zhu, L.; Li, J.; Guan, F.; Chen, T. Depletion of D3 dopamine receptor affects methamphetamine-induced expression patterns of Pde4b and Atf3. Neurosci. Lett. 2018, 665, 54–60. [Google Scholar] [CrossRef]
- Bender, A.T.; Beavo, J.A. Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use. Pharmacol. Rev. 2006, 58, 488–520. [Google Scholar] [CrossRef] [PubMed]
- Conti, M.; Beavo, J. Biochemistry and Physiology of Cyclic Nucleotide Phosphodiesterases: Essential Components in Cyclic Nucleotide Signaling. Annu. Rev. Biochem. 2007, 76, 481–511. [Google Scholar] [CrossRef]
- Janes, A.C.; Kantak, K.M.; Cherry, J.A. The involvement of type IV phosphodiesterases in cocaine-induced sensitization and subsequent pERK expression in the mouse nucleus accumbens. Psychopharmacology 2009, 206, 177–185. [Google Scholar] [CrossRef] [PubMed]
- Knapp, C.M.; Foye, M.M.; Ciraulo, D.A.; Kornetsky, C. The type IV phosphodiesterase inhibitors, Ro 20-1724 and rolipram, block the initiation of cocaine self-administration. Pharmacol. Biochem. Behav. 1999, 62, 151–158. [Google Scholar] [CrossRef]
- Thompson, B.E.; Sachs, B.D.; Kantak, K.M.; Cherry, J.A. The Type IV phosphodiesterase inhibitor rolipram interferes with drug-induced conditioned place preference but not immediate early gene induction in mice. Eur. J. Neurosci. 2004, 19, 2561–2568. [Google Scholar] [CrossRef]
- Blednov, Y.A.; Benavidez, J.M.; Black, M.; Harris, R.A. Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. Front. Neurosci. 2014, 8, 129. [Google Scholar] [CrossRef] [Green Version]
- Hu, W.; Lu, T.; Chen, A.; Huang, Y.; Hansen, R.; Chandler, L.J.; Zhang, H.-T. Inhibition of phosphodiesterase-4 decreases ethanol intake in mice. Psychopharmacology 2011, 218, 331–339. [Google Scholar] [CrossRef] [Green Version]
- Wen, R.-T.; Zhang, M.; Qin, W.-J.; Liu, Q.; Wang, W.-P.; Lawrence, A.J.; Zhang, H.-T.; Liang, J.-H.; Qing, W.-J. The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats. Alcohol. Clin. Exp. Res. 2012, 36, 2157–2167. [Google Scholar] [CrossRef] [Green Version]
- Ozburn, A.R.; Metten, P.; Potretzke, S.; Townsley, K.G.; Blednov, Y.A.; Crabbe, J.C. Effects of Pharmacologically Targeting Neuroimmune Pathways on Alcohol Drinking in Mice Selectively Bred to Drink to Intoxication. Alcohol. Clin. Exp. Res. 2019, 44, 553–566. [Google Scholar] [CrossRef]
- Bell, R.L.; Lopez, M.F.; Cui, C.; Egli, M.; Johnson, K.W.; Franklin, K.M.; Becker, H.C. Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. Addict. Biol. 2015, 20, 38–42. [Google Scholar] [CrossRef] [Green Version]
- Snider, S.E.; Hendrick, E.S.; Beardsley, P.M. Glial cell modulators attenuate methamphetamine self-administration in the rat. Eur. J. Pharmacol. 2013, 701, 124–130. [Google Scholar] [CrossRef] [Green Version]
- Snider, S.E.; Vunck, S.A.; Oord, E.J.V.D.; Adkins, D.E.; McClay, J.L.; Beardsley, P.M. The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice. Eur. J. Pharmacol. 2012, 679, 75–80. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beardsley, P.M.; Shelton, K.L.; Hendrick, E.; Johnson, K.W. The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse. Eur. J. Pharmacol. 2010, 637, 102–108. [Google Scholar] [CrossRef] [Green Version]
- Baek, J.J.; Kline, H.; Deveau, C.M.; Yamamoto, B.K. Roflumilast treatment during forced abstinence reduces relapse to methamphetamine seeking and taking. Addict. Biol. 2022, 27, e13082. [Google Scholar] [CrossRef]
- Yan, Y.; Nitta, A.; Mizuno, T.; Nakajima, A.; Yamada, K.; Nabeshima, T. Discriminative-stimulus effects of methamphetamine and morphine in rats are attenuated by cAMP-related compounds. Behav. Brain Res. 2006, 173, 39–46. [Google Scholar] [CrossRef]
- O’Donnell, J.M. William Harvey Research Conference on PDE inhibitors: Drugs with an expanding range of therapeutic uses. Expert Opin. Investig. Drugs 2000, 9, 621–625. [Google Scholar] [CrossRef] [PubMed]
- Liebenberg, N.; Harvey, B.H.; Brand, L.; Brink, C.B. Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression. Behav. Pharmacol. 2010, 21, 540–547. [Google Scholar] [CrossRef]
- Zhang, H.-T.; Huang, Y.; Masood, A.; Stolinski, L.R.; Li, Y.; Zhang, L.; Dlaboga, D.; Jin, S.-L.C.; Conti, M.; O’Donnell, J.M. Anxiogenic-Like Behavioral Phenotype of Mice Deficient in Phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 2007, 33, 1611–1623. [Google Scholar] [CrossRef] [Green Version]
- O’Donnell, J.M. Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J. Pharmacol. Exp. Ther. 1993, 264, 1168–1178. [Google Scholar]
- O’Donnell, J.M.; Frith, S.A. Behavioral Effects of Family-Selective Inhibitors of Cyclic Nucleotide Phosphodiesterases. Pharmacol. Biochem. Behav. 1999, 63, 185–192. [Google Scholar] [CrossRef]
- Wang, Z.-Z.; Zhang, Y.; Zhang, H.-T.; Li, Y.-F. Phosphodiesterase: An Interface Connecting Cognitive Deficits to Neuropsychiatric and Neurodegenerative Diseases. Curr. Pharm. Des. 2014, 21, 303–316. [Google Scholar] [CrossRef]
- Zhang, H.; Crissman, A.M.; Dorairaj, N.R.; Chandler, L.J.; O’Donnell, J.M. Inhibition of Cyclic AMP Phosphodiesterase (PDE4) Reverses Memory Deficits Associated with NMDA Receptor Antagonism. Neuropsychopharmacology 2000, 23, 198–204. [Google Scholar] [CrossRef]
- Snyder, G.L.; Vanover, K.E. PDE Inhibitors for the Treatment of Schizophrenia. Adv. Neurobiol. 2017, 17, 385–409. [Google Scholar] [CrossRef]
- Fusco, F.; Giampa, C. Phosphodiesterases as Therapeutic Targets for Huntington’s Disease. Curr. Pharm. Des. 2014, 21, 365–377. [Google Scholar] [CrossRef]
- Wang, H.; Zhang, F.-F.; Xu, Y.; Fu, H.-R.; Wang, X.-D.; Wang, L.; Chen, W.; Xu, X.-Y.; Gao, Y.-F.; Zhang, J.-G.; et al. The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice. Int. J. Neuropsychopharmacol. 2020, 23, 700–711. [Google Scholar] [CrossRef]
- Ramirez, A.D.; Smith, S.M. Regulation of dopamine signaling in the striatum by phosphodiesterase inhibitors: Novel therapeutics to treat neurological and psychiatric disorders. Cent. Nerv. Syst. Agents Med. Chem. 2015, 14, 72–82. [Google Scholar] [CrossRef] [PubMed]
- Ray, L.A.; Bujarski, S.; Shoptaw, S.; Roche, D.J.; Heinzerling, K.; Miotto, K. Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. Neuropsychopharmacology 2017, 42, 1776–1788. [Google Scholar] [CrossRef] [Green Version]
- Burnette, E.M.; Baskerville, W.-A.; Grodin, E.N.; Ray, L.A. Ibudilast for alcohol use disorder: Study protocol for a phase II randomized clinical trial. Trials 2020, 21, 1–19. [Google Scholar] [CrossRef]
- Cummings, J.R.; Tomiyama, A.J.; Ray, L.A. Does the Neuroimmune Modulator Ibudilast Alter Food Craving? Results in a Sample with Alcohol Use Disorder. J. Addict. Med. 2018, 12, 410–417. [Google Scholar] [CrossRef]
- Deyoung, D.Z.; Heinzerling, K.G.; Swanson, A.-N.; Tsuang, J.; Furst, B.A.; Yi, Y.; Wu, Y.N.; Moody, D.E.; Andrenyak, D.M.; Shoptaw, S.J. Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment. J. Clin. Psychopharmacol. 2016, 36, 347–354. [Google Scholar] [CrossRef] [Green Version]
- Heinzerling, K.G.; Briones, M.; Thames, A.D.; Hinkin, C.H.; Zhu, T.; Wu, Y.N.; Shoptaw, S.J. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder. J. Neuroimmune Pharmacol. 2019, 15, 238–248. [Google Scholar] [CrossRef]
- Li, M.J.; Briones, M.S.; Heinzerling, K.G.; Kalmin, M.M.; Shoptaw, S.J. Ibudilast attenuates peripheral inflammatory effects of methamphetamine in patients with methamphetamine use disorder. Drug Alcohol Depend. 2020, 206, 107776. [Google Scholar] [CrossRef]
- Metz, V.E.; Jones, J.D.; Manubay, J.; Sullivan, M.A.; Mogali, S.; Segoshi, A.; Madera, G.; Johnson, K.W.; Comer, S.D. Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 2017, 42, 1825–1832. [Google Scholar] [CrossRef]
- Worley, M.J.; Heinzerling, K.G.; Roche, D.J.; Shoptaw, S. Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study. Drug Alcohol Depend. 2016, 162, 245–250. [Google Scholar] [CrossRef] [Green Version]
- Houslay, M.D.; Schafer, P.; Zhang, K.Y. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discov. Today 2005, 10, 1503–1519. [Google Scholar] [CrossRef]
- Mori, F.; Pérez-Torres, S.; De Caro, R.; Porzionato, A.; Macchi, V.; Beleta, J.; Gavaldà, A.; Palacios, J.; Mengod, G. The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. J. Chem. Neuroanat. 2010, 40, 36–42. [Google Scholar] [CrossRef] [Green Version]
- Burkovetskaya, M.E.; Liu, Q.; Vadukoot, A.K.; Gautam, N.; Alnouti, Y.; Kumar, S.; Miczek, K.; Buch, S.; Hopkins, C.R.; Guo, M. KVA-D-88, a Novel Preferable Phosphodiesterase 4B Inhibitor, Decreases Cocaine-Mediated Reward Properties in Vivo. ACS Chem. Neurosci. 2020, 11, 2231–2242. [Google Scholar] [CrossRef] [PubMed]
- Jimenez Chavez, C.L.; Bryant, C.D.; Munn-Chernoff, M.A.; Szumlinski, K.K. Selective Inhibition of PDE4B Reduces Binge Drinking in Two C57BL/6 Substrains. Int. J. Mol. Sci. 2021, 22, 5443. [Google Scholar] [CrossRef]
- Naganuma, K.; Omura, A.; Maekawara, N.; Saitoh, M.; Ohkawa, N.; Kubota, T.; Nagumo, H.; Kodama, T.; Takemura, M.; Ohtsuka, Y.; et al. Discovery of selective PDE4B inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 3174–3176. [Google Scholar] [CrossRef]
- Zhang, C.; Xu, Y.; Zhang, H.-T.; Gurney, M.E.; O’Donnell, J.M. Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System. Sci. Rep. 2017, 7, 40115. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fox, D., 3rd; Burgin, A.B.; Gurney, M.E. Structural basis for the design of selective phosphodiesterase 4b inhibitors. Cell Signal. 2014, 26, 657–663. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hagen, T.J.; Mo, X.; Burgin, A.B.; Fox, D., 3rd; Zhang, Z.; Gurney, M.E. Discovery of triazines as selective pde4b versus pde4d inhibitors. Bioorg. Med. Chem. Lett. 2014, 24, 4031–4034. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Robichaud, A.; Savoie, C.; Stamatiou, P.B.; Lachance, N.; Jolicoeur, P.; Rasori, R.; Chan, C.C. Assessing the emetic potential of PDE4 inhibitors in rats. Br. J. Pharmacol. 2002, 135, 113–118. [Google Scholar] [CrossRef] [Green Version]
- Wilson, N.M.; Gurney, M.E.; Dietrich, W.D.; Atkins, C.M. Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury. PLoS ONE 2017, 12, e0178013. [Google Scholar] [CrossRef]
- Johansson, E.M.; Sanabra, C.; Mengod, G. Sex-related differences of cAMP-specific PDE4B3 mRNA in oligodendrocytes following systemic inflammation. Glia 2012, 60, 1815–1825. [Google Scholar] [CrossRef] [Green Version]
- Nicolas, C.; Zlebnik, N.E.; Farokhnia, M.; Leggio, L.; Ikemoto, S.; Shaham, Y. Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review. Pharm. Rev. 2022, 74, 119–140. [Google Scholar] [CrossRef] [PubMed]
- Cullity, E.R.; Guerin, A.A.; Perry, C.J.; Kim, J.H. Examining Sex Differences in Conditioned Place Preference or Aversion to Methamphetamine in Adolescent and Adult Mice. Front. Pharmacol. 2021, 12, 770614. [Google Scholar] [CrossRef]
- Ruda-Kucerova, J.; Amchova, P.; Babinska, Z.; Dusek, L.; Micale, V.; Sulcova, A. Sex Differences in the Reinstatement of Methamphetamine Seeking after Forced Abstinence in Sprague-Dawley Rats. Front. Psychiatry 2015, 6, 91. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reichel, C.M.; Chan, C.H.; Ghee, S.M.; See, R.E. Sex differences in escalation of methamphetamine self-administration: Cognitive and motivational consequences in rats. Psychopharmacology 2012, 223, 371–380. [Google Scholar] [CrossRef] [Green Version]
- Cox, B.M.; Young, A.B.; See, R.E.; Reichel, C.M. Sex differences in methamphetamine seeking in rats: Impact of oxytocin. Psychoneuroendocrinology 2013, 38, 2343–2353. [Google Scholar] [CrossRef] [Green Version]
- Avila, J.A.; Memos, N.; Aslan, A.; Andrejewski, T.; Luine, V.N.; Serrano, P.A. Voluntary oral methamphetamine increases memory deficits and contextual sensitization during abstinence associated with decreased PKMζ and increased κOR in the hippocampus of female mice. J. Psychopharmacol. 2021, 35, 1240–1252. [Google Scholar] [CrossRef]
- Ruan, Q.T.; Yazdani, N.; Blum, B.C.; Beierle, J.A.; Lin, W.; Coelho, M.A.; Fultz, E.K.; Healy, A.F.; Shahin, J.R.; Kandola, A.K.; et al. A Mutation in Hnrnph1 That Decreases Methamphetamine-Induced Reinforcement, Reward, and Dopamine Release and Increases Synaptosomal hnRNP H and Mitochondrial Proteins. J. Neurosci. 2020, 40, 107–130. [Google Scholar] [CrossRef]
- Brown, C.N.; Fultz, E.K.; Page, A.; Lustig, E.; Shahin, J.R.; Flaherty, D.; Healy, A.F.; Kippin, T.E.; Szumlinski, K.K. Evidence that Homer2 within the nucleus accumbens regulates methamphetamine reward and reinforcement: Transgenic studies. Front. Psychiatry 2020, 11, 11. [Google Scholar] [CrossRef] [PubMed]
- Szumlinski, K.K.; Lominac, K.D.; Campbell, R.R.; Cohen, M.; Fultz, E.K.; Brown, C.N.; Miller, B.W.; Quadir, S.G.; Martin, D.; Thompson, A.B.; et al. Methamphetamine addiction vulnerability: The glutamate, the bad and the ugly. Biol. Psychiatry 2017, 81, 959–970. [Google Scholar] [CrossRef] [PubMed]
- Bowyer, J.F.; Ali, S. High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 2006, 60, 521–532. [Google Scholar] [CrossRef]
- Loftis, J.M.; Choi, D.; Hoffman, W.; Huckans, M.S. Methamphetamine causes persistent immune dysregulation: A cross-species, translational report. Neurotox. Res. 2011, 20, 59–68. [Google Scholar] [CrossRef] [Green Version]
- Schuster, C.R.; Fischman, M.W. Amphetamine toxicity: Behavioral and neuropathological indexes. In Behavioral Pharmacology; Springer: Boston, MA, USA, 1975; Volume 4, pp. 181–194. [Google Scholar]
- Sekine, Y.; Ouchi, Y.; Sugihara, G.; Takei, N.; Yoshikawa, E.; Nakamura, K.; Iwata, Y.; Tsuchiya, K.J.; Suda, S.; Suzuki, K.; et al. Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 2008, 28, 5756–5761. [Google Scholar] [CrossRef]
- Yamamoto, B.K.; Raudensky, J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J. Neuroimmune Pharmacol. 2008, 3, 203–217. [Google Scholar] [CrossRef] [Green Version]
- Gonçalves, J.; Baptista, S.; Martins, T.; Milhazes, N.; Borges, F.; Ribeiro, C.F.; Malva, J.O.; Silva, A.P. Methamphetamine-induced neuroinflammation and neuronal dysfunction in the mice hippocampus: Preventive effect of indomethacin. Eur. J. Neurosci. 2010, 31, 315–326. [Google Scholar] [CrossRef]
- Thomas, D.M.; Walker, P.D.; Benjamins, J.A.; Geddes, T.J.; Kuhn, D.M. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J. Pharm. Exp. Ther. 2004, 311, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shabani, S.; Dobbs, L.K.; Ford, M.M.; Mark, G.P.; Finn, D.A.; Phillips, T.J. A genetic animal model of differential sensitivity to methamphetamine reinforcement. Neuropharmacology 2012, 62, 2169–2177. [Google Scholar] [CrossRef] [Green Version]
- Wheeler, J.M.; Reed, C.; Burkhart-Kasch, S.; Li, N.; Cunningham, C.L.; Janowsky, A.; Franken, F.H.; Wiren, K.M.; Hashimoto, J.G.; Scibelli, A.C.; et al. Genetically correlated effects of selective breeding for high and low methamphetamine consumption. Genes Brain Behav. 2009, 8, 758–771. [Google Scholar] [CrossRef]
- Reed, C.; Baba, H.; Zhu, Z.; Erk, J.; Mootz, J.R.; Varra, N.M.; Williams, R.W.; Phillips, T.J. A Spontaneous Mutation in Taar1 Impacts Methamphetamine-Related Traits Exclusively in DBA/2 Mice from a Single Vendor. Front. Pharm. 2018, 8, 993. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Phillips, T.J.; Roy, T.; Aldrich, S.J.; Baba, H.; Erk, J.; Mootz, J.R.K.; Reed, C.; Chesler, E.J. Confirmation of a Causal Taar1 Allelic Variant in Addiction-Relevant Methamphetamine Behaviors. Front. Psychiatry 2021, 12, 725839. [Google Scholar] [CrossRef]
- Bryant, C.D.; Zhang, N.N.; Sokoloff, G.; Fanselow, M.S.; Ennes, H.S.; Palmer, A.A.; McRoberts, J.A. Behavioral Differences among C57BL/6 Substrains: Implications for Transgenic and Knockout Studies. J. Neurogenet. 2008, 22, 315–331. [Google Scholar] [CrossRef]
- Bryant, C.D.; Bagdas, D.; Goldberg, L.R.; Khalefa, T.; Reed, E.R.; Kirkpatrick, S.L.; Kelliher, J.C.; Chen, M.M.; Johnson, W.E.; Mulligan, M.K.; et al. C57BL/6 substrain differences in inflammatory and neuropathic nociception and genetic mapping of a major quantitative trait locus underlying acute thermal nociception. Mol. Pain 2019, 15, 1744806918825046. [Google Scholar] [CrossRef] [Green Version]
- Kirkpatrick, S.L.; Bryant, C.D. Behavioral architecture of opioid reward and aversion in C57BL/6 substrains. Front. Behav. Neurosci. 2015, 8, 450. [Google Scholar] [CrossRef] [Green Version]
- Kumar, V.; Kim, K.; Joseph, C.; Kourrich, S.; Yoo, S.-H.; Huang, H.C.; Vitaterna, M.H.; De Villena, F.P.-M.; Churchill, G.; Bonci, A.; et al. C57BL/6N Mutation in Cytoplasmic FMRP interacting protein 2 Regulates Cocaine Response. Science 2013, 342, 1508–1512. [Google Scholar] [CrossRef] [Green Version]
- Matsuo, N.; Takao, K.; Nakanishi, K.; Yamasaki, N.; Tanda, K.; Miyakawa, T. Behavioral profiles of three C57BL/6 substrains. Front. Behav. Neurosci. 2010, 4, 29. [Google Scholar] [CrossRef] [Green Version]
- Kirkpatrick, S.L.; Goldberg, L.R.; Yazdani, N.; Babbs, R.K.; Wu, J.; Reed, E.R.; Jenkins, D.F.; Bolgioni, A.F.; Landaverde, K.I.; Luttik, K.P.; et al. Cytoplasmic FMR1-Interacting Protein 2 Is a Major Genetic Factor Underlying Binge Eating. Biol. Psychiatry 2017, 81, 757–769. [Google Scholar] [CrossRef] [Green Version]
- Bryant, C.D.; Healy, A.F.; Ruan, Q.T.; Coehlo, M.A.; Lustig, E.; Yazdani, N.; Luttik, K.P.; Tran, T.; Swancy, I.; Brewin, L.W.; et al. Sex-dependent effects of an Hnrnph1 mutation on fentanyl addiction-relevant behaviors but not antinociception in mice. Genes Brain Behav. 2021, 20, e12711. [Google Scholar] [CrossRef]
- Milesi-Hallé, A.; Hendrickson, H.P.; Laurenzana, E.M.; Gentry, W.B.; Owens, S.M. Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats. Toxicol. Appl. Pharmacol. 2005, 209, 203–213. [Google Scholar] [CrossRef]
- Ohia-Nwoko, O.; Haile, C.N.; Kosten, T.A. Sex differences in the acute locomotor response to methamphetamine in BALB/c mice. Behav. Brain Res. 2017, 327, 94–97. [Google Scholar] [CrossRef]
- Cornish, J.L.; Prasad, A.A. Sex Differences in Substance Use Disorders: A Neurobiological Perspective. Front. Glob. Women’s Health 2021, 2, 778514. [Google Scholar] [CrossRef]
- Quigley, J.A.; Logsdon, M.K.; Turner, C.A.; Gonzalez, I.L.; Leonardo, N.B.; Becker, J.B. Sex differences in vulnerability to addiction. Neuropharmacology 2021, 187, 108491. [Google Scholar] [CrossRef]
- Yoest, K.E.; Quigley, J.A.; Becker, J.B. Rapid effects of ovarian hormones in dorsal striatum and nucleus accumbens. Horm. Behav. 2018, 104, 119–129. [Google Scholar] [CrossRef]
- Osborne, B.F.; Turano, A.; Schwarz, J.M. Sex Differences in the Neuroimmune System. Curr. Opin. Behav. Sci. 2018, 23, 118–123. [Google Scholar] [CrossRef]
- Parks, R.J.; Ray, G.; Bienvenu, L.A.; Rose, R.A.; Howlett, S.E. Sex differences in SR Ca2+ release in murine ventricular myocytes are regulated by the cAMP/PKA pathway. J. Mol. Cell. Cardiol. 2014, 75, 162–173. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Honeywell, K.M.; Doren, E.V.; Szumlinski, K.K. Selective Inhibition of PDE4B Reduces Methamphetamine Reinforcement in Two C57BL/6 Substrains. Int. J. Mol. Sci. 2022, 23, 4872. https://doi.org/10.3390/ijms23094872
Honeywell KM, Doren EV, Szumlinski KK. Selective Inhibition of PDE4B Reduces Methamphetamine Reinforcement in Two C57BL/6 Substrains. International Journal of Molecular Sciences. 2022; 23(9):4872. https://doi.org/10.3390/ijms23094872
Chicago/Turabian StyleHoneywell, Kevin M., Eliyana Van Doren, and Karen K. Szumlinski. 2022. "Selective Inhibition of PDE4B Reduces Methamphetamine Reinforcement in Two C57BL/6 Substrains" International Journal of Molecular Sciences 23, no. 9: 4872. https://doi.org/10.3390/ijms23094872